> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Coherus BioSciences’ Yusimry
- URL: https://www.fdaweb.com/fda-approves-coherus-biosciences-yusimry/
- Published: 2022-01-03T12:00:00.000Z
- Updated: 2026-09-14T17:27:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150845

FDA has approved Coherus BioSciences’ Yusimry (adalimumab-aqvh), a biosimilar form of AbbVie’s Humira (adalimumab). The *American Journal of Managed Care* [reports](https://www.ajmc.com/view/yusimry-the-seventh-adalimumab-biosimilar-gains-fda-approval?ref=fdaweb.com) it is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.

Yusimry is the seventh Humira biosimilar approved by FDA. The manufacturers of all the biosimilars have reached an agreement with AbbVie to delay the launch of their products until various dates in 2023.